Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 24 April 2012 | By Louise Zornoza,
Australia's Therapeutic Goods Administration (TGA) is seeking comment from interested parties on draft guidance Evidence Required to Support Indications for Listed Medicines (excluding sunscreens and disinfectants).
The draft specifies the type of evidence required to support indications made for listed (low risk) medicines (including weight loss products) and is intended to replace the Guidelines for Levels and Kinds of Evidence to Support Indications and Claims for Non-Registerable Medicines, including Complementary Medicines and other Listable Medicines.
Read more:
TGA - Evidence Required to Support Indications for Listed Medicines (excluding sunscreens and disinfectants)
TGA - Guidelines for Levels and Kinds of Evidence to Support Indications and Claims for Non-Registerable Medicines, including Complementary Medicines and other Listable Medicines
More Breaking News from RegLink
Tags: Indication, pharmaceutical, claims, label, australia, safety, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.